Adefovir (Synonyms: GS-0393; PMEA)

Name: Adefovir
Brand: MedChemExpress
SKU: HY-B1826
Rating: 4.5 (1 reviews)

Cat. No.: HY-B1826 Purity: 99.55%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC₅₀ of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses.

For research use only. We do not sell to patients.

Adefovir Chemical Structure

CAS No. : 106941-25-7

Size	Price	Stock	Quantity
25 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 80	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 120	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Adefovir:

Adefovir-d4 diphosphate triethylamine Get quote
Adefovir-d₄ Get quote

1 Publications Citing Use of MCE Adefovir

•Molecules. 2022 May 18;27(10):3223. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

HBV^[1]^[2]^[3];
DNA polymerase^[1]^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
C-33-A	IC₅₀	7.8 μM Compound: 1, PMEA	Antiproliferative activity against human C33A cells after 72 hrs by flow cytometric analysis Antiproliferative activity against human C33A cells after 72 hrs by flow cytometric analysis	[PMID: 24686012]
C3H/3T3	EC₅₀	0.53 μM Compound: PMEA, Adefovir	Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days	[PMID: 18556209]
C3H/3T3	EC₅₀	2.1 μM Compound: PMEA	Antiviral against Moloney murine sarcoma virus infected in mouse C3H/3T3 cells assessed as inhibition of virus-induced cell transformation after 6 days post infection by microscopic analysis Antiviral against Moloney murine sarcoma virus infected in mouse C3H/3T3 cells assessed as inhibition of virus-induced cell transformation after 6 days post infection by microscopic analysis	[PMID: 21429755]
C8166	EC₅₀	1.7 μM Compound: PMEA	Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells	10.1016/0960-894X(95)00208-B
C8166	EC₅₀	7 μM Compound: PMEA, Adefovir	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 21803462]
CCRF-CEM	CC₅₀	≥ 250 μM Compound: PMEA	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis	[PMID: 21429755]
CCRF-CEM	EC₅₀	10.4 μM Compound: 1, PMEA, Adefovir	Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy	[PMID: 21565516]
CCRF-CEM	CC₅₀	164 μM Compound: 1, PMEA, Adefovir	Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis	[PMID: 21565516]
CCRF-CEM	EC₅₀	18 μM Compound: PMEA	In vitro anti -HIV activity tested against CEM cells infected with HIV by XTT assay In vitro anti -HIV activity tested against CEM cells infected with HIV by XTT assay	[PMID: 1323678]
CCRF-CEM	IC₅₀	24 μM Compound: 1, PMEA	Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis	[PMID: 24686012]
CCRF-CEM	EC₅₀	5.5 μM Compound: PMEA, Adefovir	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 21803462]
CCRF-CEM	EC₅₀	7 μM Compound: PMEA, adefovir	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopy Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopy	[PMID: 21745746]
CCRF-CEM	EC₅₀	7 μM Compound: PMEA	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis	[PMID: 21429755]
CCRF-CEM	EC₅₀	7.4 μM Compound: PMEA, adefovir	Antiviral activity against Human immunodeficiency virus type1 3B infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopic analysis Antiviral activity against Human immunodeficiency virus type1 3B infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopic analysis	[PMID: 21745746]
CCRF-CEM	EC₅₀	7.4 μM Compound: PMEA	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis	[PMID: 21429755]
CCRF-CEM	EC₅₀	8.2 μM Compound: 1, PMEA	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 24686012]
CCRF-CEM	EC₅₀	8.4 μM Compound: 1, PMEA	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 24686012]
CCRF-CEM	EC₅₀	8.6 μM Compound: 1, PMEA, Adefovir	Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy	[PMID: 21565516]
CHO	CC₅₀	≥ 2000 μM Compound: Adefovir	Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	CC₅₀	1.4 μM Compound: Adefovir	Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	CC₅₀	3 μM Compound: Adefovir	Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
H9	CC₅₀	> 30 μM Compound: PMEA, Adefovir	Cytotoxicity against PAP-activated human H9 cells on day 7 by MTT assay Cytotoxicity against PAP-activated human H9 cells on day 7 by MTT assay	[PMID: 21803462]
H9	EC₅₀	1.1 μM Compound: PMEA, Adefovir	Antiviral activity against 125 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity Antiviral activity against 125 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	[PMID: 21803462]
H9	EC₅₀	7.9 μM Compound: PMEA, Adefovir	Antiviral activity against 6250 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity Antiviral activity against 6250 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	[PMID: 21803462]
HEK-293T	CC₅₀	> 100 μM Compound: PMEA	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HEL 299	EC₅₀	> 183 μM Compound: 3a, PMEA	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HEL 299	EC₅₀	> 183 μM Compound: 3a, PMEA	Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HEL 299	CC₅₀	211 μM Compound: 3a, PMEA	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	[PMID: 17893157]
HeLa	CC₅₀	> 250 μM Compound: 1, PMEA, Adefovir	Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis	[PMID: 21565516]
HeLa	IC₅₀	181 μM Compound: 1, PMEA	Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis	[PMID: 24686012]
HepG2	IC₅₀	42.1 μM Compound: PMEA, 1	Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay	[PMID: 17888662]
HepG2 2.2.15	IC₅₀	0.517 μM Compound: adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication after 9 days by PCR Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication after 9 days by PCR	[PMID: 20000776]
HepG2 2.2.15	IC₅₀	0.517 μM Compound: Adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 9 days by fluorescence PCR method Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 9 days by fluorescence PCR method	[PMID: 23353737]
HepG2 2.2.15	EC₅₀	1.3 μM Compound: Adefovir	Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	1.6 μM Compound: Adefovir	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	1.9 μM Compound: Adefovir	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	2.1 μM Compound: Adefovir	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb	[PMID: 21930377]
HepG2 2.2.15	CC₅₀	200 μM Compound: Adefovir	Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay	[PMID: 28082068]
HepG2 2.2.15	IC₅₀	215 μM Compound: Adefovir	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA	[PMID: 25650312]
HepG2 2.2.15	IC₅₀	257 μM Compound: Adefovir	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA	[PMID: 25650312]
HepG2 2.2.15	IC₅₀	286 μM Compound: Adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg production after 9 days by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg production after 9 days by ELISA	[PMID: 23353737]
HepG2 2.2.15	IC₅₀	286 μM Compound: adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg level after 9 days by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg level after 9 days by ELISA	[PMID: 20000776]
HepG2 2.2.15	IC₅₀	305 μM Compound: Adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg production after 9 days by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg production after 9 days by ELISA	[PMID: 23353737]
HepG2 2.2.15	IC₅₀	305 μM Compound: adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg level after 9 days by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg level after 9 days by ELISA	[PMID: 20000776]
HepG2 2.2.15	CC₅₀	490 μM Compound: Adefovir	Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay	[PMID: 25650312]
HepG2 2.2.15	EC₅₀	5.5 μM Compound: Adefovir	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	CC₅₀	540 μM Compound: Adefovir	Cytotoxicity against human HepG2(2.2.15) cells compound treated for 48 hrs followed by incubation for 9 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells compound treated for 48 hrs followed by incubation for 9 days by MTT assay	[PMID: 23353737]
HepG2 2.2.15	CC₅₀	57 μM Compound: adefovir	Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay	[PMID: 17499889]
HepG2 2.2.15	EC₅₀	7.8 μM Compound: Adefovir	Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth	[PMID: 21930377]
Huh-7	EC₅₀	1.3 μM Compound: adefovir	Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.5 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.6 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.6 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.8 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	6 μM Compound: PMEA, Adefovir	Antiviral activity against Hepatitis B virus infected in human HuH7 cells assessed as reduction in viral DNA level treated day 3 to day 8 post transfection by real time quantitative PCR analysis Antiviral activity against Hepatitis B virus infected in human HuH7 cells assessed as reduction in viral DNA level treated day 3 to day 8 post transfection by real time quantitative PCR analysis	[PMID: 21803462]
Huh-7	EC₅₀	7.7 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
L1210	IC₅₀	3 μM Compound: 1, PMEA	Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counting analysis Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counting analysis	[PMID: 24686012]
MT4	EC₅₀	22 μM Compound: PMEA	Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells	10.1016/0960-894X(95)00208-B
PBMC	CC₅₀	> 30 μM Compound: PMEA, Adefovir	Cytotoxicity against PAP-activated human PBMC on day 7 by MTT assay Cytotoxicity against PAP-activated human PBMC on day 7 by MTT assay	[PMID: 21803462]
Vero	IC₅₀	119 μM Compound: 1	Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro	[PMID: 8021925]
WI-38	CC₅₀	124.7 μM Compound: PMEA	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	95.8 μM Compound: PMEA	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

In Vitro

Studies to elucidate the mechanism of action of Adefovir against herpesvirus replication reveals that the phosphorylation of Adefovir occurred intracellularly and is carried out by host cellular enzymes. The diphosphorylated derivatives of Adefovir targeted the viral DNA polymerase and also acted as DNA chain terminators. Adenylate kinase is shown to be responsible for the first phosphorylation, which was followed by ADP kinase and creatine kinase, forming Adefovir diphosphate^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Unaffected by food, Adefovir achieves 60% oral bioavailability. Its half-life is 12-30 hours and Adefovir undergoes renal excretion without significant metabolites. Adefovir does not substantially affect the cytochrome P450 system^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

273.19

Formula

C₈H₁₂N₅O₄P

CAS No.

106941-25-7

Appearance

Solid

Color

White to off-white

SMILES

NC1=C2N=CN(CCOCP(O)(O)=O)C2=NC=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

0.1 M NaOH : 10 mg/mL (36.60 mM; ultrasonic and adjust pH to 10 with NaOH)

H₂O : < 0.1 mg/mL (insoluble)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.6605 mL	18.3023 mL	36.6046 mL
5 mM	0.7321 mL	3.6605 mL	7.3209 mL
10 mM	0.3660 mL	1.8302 mL	3.6605 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.74%

Select Batch:

Data Sheet (273 KB) SDS (479 KB)

COA (246 KB) HNMR (117 KB) RP-HPLC (191 KB)

Handling Instructions (2659 KB)

References

[1]. X.-X.Zhou, et al. 7.11 - Deoxyribonucleic Acid Viruses: Antivirals for Herpesviruses and Hepatitis B Virus. Comprehensive Medicinal Chemistry II. Volume 7, 2007, Pages 295-327.

[2]. Marcellin P, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):808-16. [Content Brief]

[3]. Leah A.Burke, et al. 155 - Drugs to Treat Viral Hepatitis. Infectious Diseases. Volume 2, 2017, Pages 1327-1332.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

0.1 M NaOH	1 mM	3.6605 mL	18.3023 mL	36.6046 mL	91.5114 mL
	5 mM	0.7321 mL	3.6605 mL	7.3209 mL	18.3023 mL
	10 mM	0.3660 mL	1.8302 mL	3.6605 mL	9.1511 mL
	15 mM	0.2440 mL	1.2202 mL	2.4403 mL	6.1008 mL
	20 mM	0.1830 mL	0.9151 mL	1.8302 mL	4.5756 mL
	25 mM	0.1464 mL	0.7321 mL	1.4642 mL	3.6605 mL
	30 mM	0.1220 mL	0.6101 mL	1.2202 mL	3.0504 mL

Adefovir Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Adefovir (Synonyms: GS-0393; PMEA)

Customer Review

Other Forms of Adefovir:

1 Publications Citing Use of MCE Adefovir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Adefovir Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Adefovir (Synonyms: GS-0393; PMEA)

Customer Review

Other Forms of Adefovir:

Adefovir Related Antibodies

1 Publications Citing Use of MCE Adefovir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Adefovir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Adefovir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report